Cellcyte Genetics (SHPN) 8-K Entry into a Material Definitive Agreement

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 24, 2010
Date of Report (Date of earliest event reported)

CELLCYTE GENETICS CORPORATION
(Exact name of registrant as specified in its charter)

Nevada	000-52238	86-1127046
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14205 SE 36th St. Suite 100, Bellevue Washington	98006
(Address of principal executive offices)	(Zip Code)

(425) 519-3659
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[     ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[     ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[     ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[     ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 1 – Registrant’s Business and Operations

Item 1.01 Entry Into a Material Definitive Agreement

On September _9_, 2010, the Company entered into a collaboration agreement (the “Agreement’) with the Fred Hutchinson Cancer Research Center (“FHCR”) in Seattle, Washington, to evaluate the effectiveness of Cellcyte’s CCG-E45 bioreactor product as a supplement or replacement to FHCR’s current methods of culturing specific cell lines.

The CCG-E45 bioreactor product is a cell expansion devise that allows the culture of cells at high density and under precisely controlled oxygenation, providing an alternative to standard cell cutler methodologies.  It is hoped that through this collaborative research, FHCR will realize a substantial increase in laboratory productivity.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CELLCYTE GENETICS CORPORATION
Date:September 24, 2010.	_______________________________________ Name:  John M. Fluke Title:     Interim Principal Executive Officer